{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:07:17Z","timestamp":1792292837023,"version":"4.4.0"},"reference-count":81,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T00:00:00Z","timestamp":1665273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Faculty of Pharmaceutical Sciences, Chulalongkorn University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Glaucoma is one of the leading causes of irreversible blindness worldwide. It is characterized by progressive optic neuropathy in association with damage to the optic nerve head and, subsequently, visual loss if it is left untreated. Among the drug classes used for the long-term treatment of open-angle glaucoma, prostaglandin analogues (PGAs) are the first-line treatment and are available as marketed eye drop formulations for intraocular pressure (IOP) reduction by increasing the trabecular and uveoscleral outflow. PGAs have low aqueous solubility and are very unstable (i.e., hydrolysis) in aqueous solutions, which may hamper their ocular bioavailability and decrease their chemical stability. Additionally, treatment with PGA in conventional eye drops is associated with adverse effects, such as conjunctival hyperemia and trichiasis. It has been a very challenging for formulation scientists to develop stable aqueous eye drop formulations that increase the PGAs\u2019 solubility and enhance their therapeutic efficacy while simultaneously lowering their ocular side effects. Here the physiochemical properties and chemical stabilities of the commercially available PGAs are reviewed, and the compositions of their eye drop formulations are discussed. Furthermore, the novel PGA formulations for glaucoma treatment are reviewed.<\/jats:p>","DOI":"10.3390\/pharmaceutics14102142","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T01:21:07Z","timestamp":1665364867000},"page":"2142","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Aqueous Prostaglandin Eye Drop Formulations"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7114-8991","authenticated-orcid":false,"given":"Phatsawee","family":"Jansook","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Chulalongkorn University, 254 Phyathai Road, Pathumwan, Bangkok 10330, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-1553","authenticated-orcid":false,"given":"Thorsteinn","family":"Loftsson","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, IS-107 Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zukerman, R., Harris, A., Vercellin, A.V., Siesky, B., Pasquale, L.R., and Ciulla, T.A. (2021). Molecular genetics of glaucoma: Subtype and ethnicity considerations. Genes, 12.","DOI":"10.3390\/genes12081135"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"ref_3","unstructured":"Assenmacher, M., Avraham, H.K., Avraham, S., Bala, S., Barnett, J., Basketter, D., Ben-David, Y., Berek, C., Bl\u00fcmel, J., and Bolliger, A.P. (2005). Prostaglandins. Encyclopedic Reference of Immunotoxicology, Springer."},{"key":"ref_4","first-page":"1","article-title":"Prostaglandins: A general review","volume":"1","author":"Shaw","year":"1971","journal-title":"Res. Prostaglandins"},{"key":"ref_5","first-page":"1125","article-title":"Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits","volume":"16","author":"Camras","year":"1977","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_6","first-page":"897","article-title":"Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: A review","volume":"2","author":"Russo","year":"2008","journal-title":"Clin. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"749858","DOI":"10.3389\/fphar.2021.749858","article-title":"Topical medication therapy for glaucoma and ocular hypertension","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14740338.2022.1996560","article-title":"A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension","volume":"21","author":"Katsanos","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/108076803762718105","article-title":"Hydrolysis of Bimatoprost (Lumigan) to its free acid by ocular tissue in vitro","volume":"19","author":"Davies","year":"2003","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Moussa, W.G.E.H., Farhat, R.G., Nehme, J.C., Sahyoun, M.A., Schakal, A.R., Jalkh, A.E., Karam, M.P.A., and Azar, G.G. (2018). Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and tafluprost in glaucoma patients. J. Ophthalmol., 1319628.","DOI":"10.1155\/2018\/1319628"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Najjar, A., Najjar, A., and Karaman, R. (2020). Newly developed prodrugs and prodrugs in development; an insight of the recent years. Molecules, 25.","DOI":"10.3390\/molecules25040884"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/OPX.0000000000001842","article-title":"Effect of latanoprostene bunod on optic nerve head blood flow","volume":"99","author":"Samaha","year":"2022","journal-title":"Optom. Vis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/bjophthalmol-2020-317262","article-title":"Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: A systematic literature review and a network meta-analysis","volume":"106","author":"Harasymowycz","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2013.0179","article-title":"Effects of prostaglandin analogues on aqueous humor outflow pathways","volume":"30","author":"Winkler","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1021\/js960076m","article-title":"Unified model for the corneal permeability of related and diverse compounds with respect to their physicochemical properties","volume":"85","author":"Yoshida","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17425247.2022.2017878","article-title":"Topical drug delivery to the retina: Obstacles and routes to success","volume":"19","author":"Loftsson","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"120332","DOI":"10.1016\/j.ijpharm.2021.120332","article-title":"Topical drug delivery to the posterior segment of the eye: Thermodynamic considerations","volume":"597","author":"Sripetch","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_18","unstructured":"Connors, K.A., Amidon, G.L., and Stella, V.J. (1986). Prostaglandin E2. Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists, John Wiley & Sons. [2nd ed.]."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/jps.2600611202","article-title":"Prostaglandins","volume":"61","author":"Oesterling","year":"1972","journal-title":"J. Pharm. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0076-6879(82)86216-2","article-title":"Physical chemistry, stability, and handling of prostaglandins E2, F2\u03b1, D2, and I2: A critical summary","volume":"86","author":"Stehle","year":"1982","journal-title":"Methods Enzymol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00061198-200110000-00007","article-title":"Effect of temperature and light on the stability of latanoprost and its clinical relevance","volume":"10","author":"Morgan","year":"2001","journal-title":"J. Glaucoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/02713683.2014.939763","article-title":"Stability of latanoprost in generic formulations using controlled degradation and patient usage simulation studies","volume":"40","author":"Velpandian","year":"2015","journal-title":"Curr. Eye Res."},{"key":"ref_23","first-page":"324","article-title":"Formulation design of latanoprost eye drops to improve the stability at room temperature","volume":"70","author":"Ochiai","year":"2010","journal-title":"J. Pharm. Sci. Technol."},{"key":"ref_24","first-page":"656","article-title":"Development of a stable latanoprost solution for use as eye drops","volume":"40","author":"Sawatdee","year":"2013","journal-title":"Chiang Mai J. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105758","DOI":"10.1016\/j.ejps.2021.105758","article-title":"Latanoprost-loaded cyclodextrin microaggregate suspension eye drops for enhanced bioavailability and stability","volume":"160","author":"Zhou","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpb.2015.04.032","article-title":"New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance","volume":"95","author":"Guinchard","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2011.03.006","article-title":"The stabilization mechanism of latanoprost","volume":"410","author":"Ochiai","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_28","unstructured":"Airy, S., Chiou, J., Nguyen, H., Jani, R., Gan, O., Kabra, B., Nguyen, H., and Weiner, A. (2002, January 16\u201329). Developmental preformulation studies in the design of travoprost ophthalmic solution 0.004% (TRAVANTAN\u00ae). Proceedings of the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Toronto, ON, Canada."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1586\/17469899.2.3.363","article-title":"Travoprost Z ophthalmic solution with sofZia: Clinical safety and efficacy","volume":"2","author":"Kahook","year":"2007","journal-title":"Expert Rev. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Alviset, G., Corvis, Y., Hammad, K., Lemut, J., Maury, M., Mignet, N., and Boudy, V. (2022). New preservative-free formulation for the enhanced ocular bioavailability of prostaglandin analogues in glaucoma. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020453"},{"key":"ref_31","unstructured":"Loftson, T. (2014). Drug Stability for Pharmaceutical Scientists, Academic Press."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/jop.2010.0115","article-title":"Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use","volume":"27","author":"Johnson","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1345\/aph.1R229","article-title":"Tafluprost: The first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension","volume":"46","author":"Swymer","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14656566.2017.1293654","article-title":"Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension","volume":"18","author":"Kaufman","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: The good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41433-021-01668-x","article-title":"Ocular benzalkonium chloride exposure: Problems and solutions","volume":"36","author":"Goldstein","year":"2022","journal-title":"Eye"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jddst.2018.09.007","article-title":"Topical drug delivery to the posterior segment of the eye: The effect of benzalkonium chloride on topical dexamethasone penetration into the eye in vivo","volume":"48","author":"Johannsdottir","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2147\/OPTH.S368214","article-title":"Retrospective analysis of switching bimatoprost 0.01% to bimatoprost 0.03% in patients with various types of glaucoma and ocular hypertension","volume":"16","author":"Xu","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_39","first-page":"2131","article-title":"Preservative toxicity in glaucoma medication: Clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops","volume":"7","author":"Rosin","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000192082","article-title":"Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost","volume":"41","author":"Pellinen","year":"2009","journal-title":"Ophthalmic Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2147\/OPTH.S176605","article-title":"Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: The 12-month real-life FREE study","volume":"12","author":"Economou","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kim, J.M., Park, S.W., Seong, M., Ha, S.J., Lee, J.W., Rho, S., Lee, C.E., Kim, K.N., Kim, T.W., and Sung, K.R. (2021). Comparison of the safety and efficacy between preserved and preservative-free latanoprost and preservative-free tafluprost. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060501"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/jps.2600730323","article-title":"Inclusion complexation of prostaglandin F2 alpha with gamma-cyclodextrin in solution and solid phases","volume":"73","author":"Uekama","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"ref_44","first-page":"158","article-title":"Effect of complexation with hydroxylpropyl-\u03b2-cyclodextrin on solubility, dissolution rate and chemical stability of prostaglandin E1","volume":"13","author":"Gu","year":"2004","journal-title":"J. Chin. Pharm. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/jps.2600680838","article-title":"Improvements of dissolution characteristics and chemical stability of 16,16-dimethyl-trans-\u03942-prostaglandin E1 methyl ester by cyclodextrin complexation","volume":"68","author":"Uekama","year":"1979","journal-title":"J. Pharm. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/BF00662213","article-title":"Prostaglandins and their cyclodextrin complexes","volume":"2","author":"Inaba","year":"1984","journal-title":"J. Incl. Phenom."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1023\/A:1013034615464","article-title":"Stabilizing and solubilizing effects of sulfobutyl ether \u03b2-cyclodextrin on prostaglandin E1 analog","volume":"18","author":"Uekama","year":"2001","journal-title":"Pharm. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.22270\/jddt.v9i5-s.3612","article-title":"Formulation and evaluation of tafluprost ophthalmic solution","volume":"9","author":"Kumar","year":"2019","journal-title":"J. Drug Deliv. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0091270006292626","article-title":"Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation","volume":"47","author":"Gonzalez","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/17425247.2016.1201059","article-title":"Application of lipid nanoparticles to ocular drug delivery","volume":"13","author":"Battaglia","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Jacob, S., Nair, A.B., Shah, J., Gupta, S., Boddu, S.H.S., Sreeharsha, N., Joseph, A., Shinu, P., and Morsy, M.A. (2022). Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy-An overview on recent advances. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030533"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1773-2247(11)50078-4","article-title":"Microemulsions for ocular delivery: Evaluation and characterization","volume":"21","author":"Habib","year":"2011","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jconrel.2020.10.025","article-title":"Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery","volume":"328","author":"Singh","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejpb.2004.03.033","article-title":"The potential of lipid emulsion for ocular delivery of lipophilic drugs","volume":"58","author":"Tamilvanan","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_55","first-page":"1690","article-title":"Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: An in vivo toxicity assay","volume":"15","author":"Liang","year":"2009","journal-title":"Mol. Vis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/jop.2011.0245","article-title":"A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models","volume":"28","author":"Daull","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/ICO.0b013e318255a7f8","article-title":"In vitro and In vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models","volume":"31","author":"Liang","year":"2012","journal-title":"Cornea"},{"key":"ref_58","first-page":"107","article-title":"Novasorb\u00ae cationic nanoemulsion and latanoprost: The ideal combination for glaucoma management?","volume":"2","author":"Daull","year":"2017","journal-title":"Glaucoma"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"119402","DOI":"10.1016\/j.ijpharm.2020.119402","article-title":"Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic\/pharmacodynamic properties","volume":"583","author":"Ismail","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00417-021-05536-y","article-title":"A novel ophthalmic latanoprost 0.005% nanoemulsion: A cytotoxicity study","volume":"260","author":"Tau","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3109\/10717544.2014.943336","article-title":"Liposomes in topical ophthalmic drug delivery: An update","volume":"23","author":"Agarwal","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Natarajan, J.V., Chattopadhyay, S., Ang, M., Darwitan, A., Foo, S., Zhen, M., Koo, M., Wong, T.T., and Venkatraman, S.S. (2011). Sustained release of an anti-glaucoma drug: Demonstration of efficacy of a liposomal formulation in the rabbit eye. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024513"},{"key":"ref_63","first-page":"123","article-title":"Nanomedicine for glaucoma: Liposomes provide sustained release of latanoprost in the eye","volume":"7","author":"Natarajan","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/nn4046024","article-title":"Sustained Drug Release in Nanomedicine: A Long-Acting Nanocarrier-Based Formulation for Glaucoma","volume":"8","author":"Natarajan","year":"2014","journal-title":"ACS Nano"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17425247.2020.1822322","article-title":"Emerging potential of niosomes in ocular delivery","volume":"18","author":"Verma","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Durak, S., Esmaeili Rad, M., Alp Yetisgin, A., Eda Sutova, H., Kutlu, O., Cetinel, S., and Zarrabi, A. (2020). Niosomal drug delivery systems for ocular disease-recent advances and future prospects. Nanomaterials, 10.","DOI":"10.3390\/nano10061191"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/03639045.2020.1755305","article-title":"Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma","volume":"46","author":"Fathalla","year":"2020","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.carbpol.2016.02.080","article-title":"Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment","volume":"144","author":"Cheng","year":"2016","journal-title":"Carbohydr. Polym."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"101134","DOI":"10.1016\/j.jddst.2019.101134","article-title":"Development of optimized mucoadhesive thermosensitive pluronic based in situ gel for controlled delivery of Latanoprost: Antiglaucoma efficacy and stability approaches","volume":"53","author":"Khattab","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jphp.12131","article-title":"A review of topically administered mini- tablets for drug delivery to the anterior segment of the eye","volume":"66","author":"Moosa","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.10.4.2","article-title":"Intraocular pressure reduction effect of 0.005% latanoprost eye drops in a hyaluronic acid-chitosan nanoparticle drug delivery system in albino rabbits","volume":"10","author":"Rubenicia","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.actbio.2022.03.015","article-title":"Iontophoretic ocular delivery of latanoprost-loaded nanoparticles via skin-attached electrodes","volume":"144","author":"Kim","year":"2022","journal-title":"Acta Biomater."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"102260","DOI":"10.1016\/j.nano.2020.102260","article-title":"Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment","volume":"29","author":"Schnichels","year":"2020","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Cela-Casamayor, M.A., L\u00f3pez-Cano, J.J., Bravo-Osuna, I., Andr\u00e9s-Guerrero, V., Vicario-de-la-Torre, M., Guzm\u00e1n-Navarro, M., Ben\u00edtez-Del-Castillo, J.M., Herrero-Vanrell, R., and Molina-Mart\u00ednez, I.T. (2022). Novel osmoprotective DOPC-DMPC liposomes loaded with antihypertensive drugs as potential strategy for glaucoma treatment. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071405"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.biomaterials.2013.09.032","article-title":"In vivo performance of a drug-eluting contact lens to treat glaucoma for a month","volume":"35","author":"Ciolino","year":"2014","journal-title":"Biomaterials"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"103044","DOI":"10.1016\/j.jddst.2021.103044","article-title":"Extended ocular delivery of latanoprost from niosome-laden contact lenses: In vitro characterization and in vivo studies","volume":"68","author":"Xue","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/10837450.2021.1999471","article-title":"Sustained latanoprost release from PEGylated solid lipid nanoparticle-laden soft contact lens to treat glaucoma","volume":"27","author":"Dang","year":"2022","journal-title":"Pharm. Dev. Technol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1208\/s12249-020-1622-6","article-title":"Bimatoprost imprinted silicone contact lens to treat glaucoma","volume":"21","author":"Yan","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Franca, J.R., Foureaux, G., Fuscaldi, L.L., Ribeiro, T.G., Rodrigues, L.B., Bravo, R., Castilho, R.O., Yoshida, M.I., Cardoso, V.N., and Fernandes, S.O. (2014). Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: In vitro and in vivo evaluation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095461"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.ophtha.2016.04.026","article-title":"Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: Results of a Phase II Randomized Controlled study","volume":"123","author":"Brandt","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Shukr, M.H., Ismail, S., El-Hossary, G.G., and El-Shazly, A.H. (2022). Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: Optimization using Box-Behnken design and in vivo evaluation. J. Liposome Res., 1\u201311.","DOI":"10.1080\/08982104.2022.2025828"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:48:46Z","timestamp":1760143726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,9]]},"references-count":81,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["pharmaceutics14102142"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14102142","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,9]]}}}